Pentixafor Positron Emission Tomography Scan: A New Imaging Test for Staging in Non-small Cell Lung Cancer

Phase 1

Recruiting

• Conditions: on-small cell lung cancer; Non-small cell lung cancer; Cancer - Lung - Non small cell

• Registration Number: ACTRN12615001265561
• Lead Sponsor: Oceanic Molecular Imaging

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-11-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

a.Histological diagnosis of NSCLC.
b.Requires 18F-FDG PET/CT as part of routine work-up for diagnosis and staging.
c.Competent to provide informed consent
d.Not pregnant or breastfeeding

Exclusion Criteria

Age < 40
Pregnant or breastfeeding
Lack of indication or contraindication to FDG PET

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure and compare maximum Standardized Uptake Value (SUV) in sites of primary and metastatic disease identified on FDG PET and Pentixafor PET. <br><br>[Each scan will by double read by reviewed by two qualified radiologists or nuclear medicine specialists on the day of the scan. Tracer uptake quantified using Standardized Uptake Value will be recorded for each site of suspected disease in each patient. ]

Secondary Outcome Measures

Name	Time	Method
To measure the concordance between maximum SUV in sites of disease identified on FDG PET and Pentixafor PET on a lesion by lesion basis for each patient.[Each scan will by double read by reviewed by two qualified radiologists or nuclear medicine specialists on the day of the scan. Concordant and discrepant results between the FDG and Pentixafor PET scans will be recorded in a table. ];To describe discordant results on FDG PET and Pentixafor on a lesion by lesion basis and correlate with histolopathological results or clinical follow up where this information is available. [Each scan will by double read by reviewed by two qualified radiologists or nuclear medicine specialists on the day of the scan. Concordant and discrepant results between the FDG and Pentixafor PET scans will be recorded in a table. ]